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The progressive decline in kidney function and concomitant
loss of renal 1a-hydroxylase (CYP27B1) in chronic kidney
disease (CKD) are associated with a gradual loss of
circulating 25-hydroxyvitamin D3 (25(OH)D3) and 1a,25-
dihydroxyvitamin D3 (1a,25(OH)2D3). However, only the
decrease in 1a,25(OH)2D3 can be explained by the decline of
CYP27B1, suggesting that insufficiency of both metabolites
may reflect their accelerated degradation by the key
catabolic enzyme 24-hydroxylase (CYP24). To determine
whether CYP24 is involved in causing vitamin D
insufficiency and/or resistance to vitamin D therapy
in CKD, we determined the regulation of CYP24 and
CYP27B1 in normal rats and rats treated with adenine to
induce CKD. As expected, CYP24 decreased whereas CYP27B1
increased when normal animals were rendered vitamin D
deficient. Unexpectedly, renal CYP24 mRNA and protein
expression were markedly elevated, irrespective of the
vitamin D status of the rats. A significant decrease in serum
1a,25(OH)2D3 levels was found in uremic rats; however, we
did not find a coincident decline in CYP27B1. Analysis in
human kidney biopsies confirmed the association of elevated
CYP24 with kidney disease. Thus, our findings suggest that
dysregulation of CYP24 may be a significant mechanism
contributing to vitamin D insufficiency and resistance to
vitamin D therapy in CKD.
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Vitamin D insufficiency is commonly observed in patients
with chronic kidney disease (CKD) and is causally related to
secondary hyperparathyroidism, a disorder characterized by
elevated serum-intact parathyroid hormone (iPTH) levels,
parathyroid gland hyperplasia and imbalances in bone and
mineral metabolism.1–3 Low vitamin D levels have also been
linked to the pathogenesis of other diseases related to CKD,
including diabetes,4 hypertension,5 and obesity.6,7 External
factors, such as lack of sunlight and inadequate vitamin D
intake, are recognized as important factors contributing
to vitamin D insufficiency in CKD patients;8 however,
disturbances in the regulation of key cytochrome P450
enzymes involved in the synthesis (1a-hydroxylase;
CYP27B1) and catabolism (24-hydroxylase; CYP24) of
vitamin D metabolites may also be implicated.
Vitamin D3 is synthesized in human skin from
7-dehydrocholesterol after ultraviolet light exposure and is
metabolized in the liver to form the prohormone,
25-hydroxyvitamin D3 (25(OH)D3). Circulating 25(OH)D3
provides substrate for conversion to the biologically active
hormone 1a,25-dihydroxyvitamin D3 (1a,25(OH)2D3) by
1a-hydroxylase CYP27B1 primarily expressed in renal
proximal and distal convoluted tubules.9,10 Although kidneys
produce the bulk of circulating hormones, extra-renal
expression of CYP27B1 is thought to be important for
localized production of 1a,25(OH)2D3.
11,12 The effects of
1a,25(OH)2D3 are mediated by the vitamin D receptor
expressed in target organs, including those involved in the
maintenance of calcium/phosphate homeostasis and
normal bone mineralization, immunomodulation, as well
as the regulation of cell growth and differentiation, insulin
secretion, cardiovascular function, and blood pressure
regulation.13 Vitamin D insufficiency observed in CKD is
associated with morbidity, which extends well beyond
compromised bone and mineral metabolism,14–16 and con-
tributes to increased mortality.17–20
Declining renal mass and concomitant loss of renal
CYP27B1 capacity in CKD are commonly associated
with reductions in circulating levels of both 1a,25(OH)2D3
and 25(OH)D3.
21,22 However, observations of low serum
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1a,25(OH)2D3 have not been consistently linked with
decreases in renal CYP27B1 expression, as levels of CYP27B1
mRNA may in some cases remain unchanged in CKD
patients deficient in 1a,25(OH)2D3.
23 Moreover, diminishing
CYP27B1 expression levels cannot directly account for
the progressive loss of 25(OH)D3. These findings suggest
that additional intrinsic mechanisms may underlie declining
vitamin D metabolites, namely, 25(OH)D3 and
1a,25D(OH)2D3, in renal disease.
Apart from disturbances in 1a,25(OH)2D3 synthesis,
accelerated catabolism may also have a role in lowering
circulating 1a,25(OH)2D3 and 25(OH)D3 levels in CKD
patients. The mitochondrial cytochrome P450 enzyme
CYP24 has a unique role in the catabolism of both
1a,25(OH)2D3 and 25(OH)D3.
24,25 Deletion of the CYP24
gene significantly increases the half-lives of circulating
1a,25(OH)2D3 and 25(OH)D3 and renders CYP24-null
animals hypersensitive to vitamin D, thus confirming the
importance of CYP24 in vitamin D homeostasis.26,27
Normally, CYP24 protein seems to be most abundant in
the proximal tubule of the kidney, with lower expression
observed in distal segments.28,29 However, CYP24 is also
ubiquitously expressed in vitamin D target tissues external to
the kidney.30 In some disease states, such as genetically linked
hypophosphatemia31–33 and certain types of cancer,34–39
CYP24 expression and activity is enhanced and may be
linked to both vitamin D insufficiency, as well as increased
resistance to vitamin D treatment often associated with these
pathologies. Given the important functional role of CYP24 in
tightly regulating the biological activity of 1a,25(OH)2D3 and
25(OH)D3, overexpression of this enzyme in kidney can also
have a significant impact on vitamin D status.
To determine whether CYP24 and CYP27B1 expression is
altered in uremia, we investigated the regulation of these
enzymes in normal and adenine-induced uremic rats, as
well as in renal biopsy tissue from patients with kidney
disease. Our findings suggest that dysregulation of CYP24
may be a significant mechanism contributing to vitamin D
insufficiency and resistance to vitamin D therapy in CKD.
RESULTS
Renal CYP24 and CYP27B1 gene and protein expression in
uremic vs normal rats
The effects of uremia on the expression of renal CYP24 and
CYP27B1 mRNA and protein were examined using the
adenine rat model of CKD. Previous studies using adenine-
treated rats have shown that this model exhibits all key
features of CKD pathology, including elevated creatinine,
iPTH and fibroblast growth factor 23 (FGF23), hypocalcemia,
hyperphosphatemia, and reduced serum 1a,25(OH)2D3.
40–42
Uremia in adenine-treated rats was evident from elevated
mean serum creatinine levels of 1.86±0.20mg/dl compared
with 0.39±0.17mg/dl in normal rats (Po0.001). Plasma
iPTH and serum FGF23 levels were elevated in uremic rats,
serum calcium was decreased, serum phosphorus was
increased (Table 1), and serum 1a,25(OH)2D3 declined
(59.20±9.80 pg/ml nonuremic vs 15.20±3.16 pg/ml uremic;
Po0.01; Figure 1d). Although serum 25(OH)D3 levels
remained unchanged (23.90±2.09 ng/ml nonuremic vs
25.90±1.90 ng/ml uremic; Figure 1e) 1 week after adenine
treatment, a decline of about 20% in 25(OH)D3 levels was
observed at 6 and 8 weeks after treatment compared with
normal control animals (Figure 1f). These findings are
consistent with the accelerated elimination of 25(OH)D3,
raising the possibility that elevated CYP24 may have a role in
declining vitamin D status in CKD patients.
Examination of renal mRNA revealed a greater than
fivefold increase in CYP24 expression after adenine treatment
(Po0.001; Figure 1a). Consistent with this finding, an
increased CYP24 protein expression was also observed in
uremic kidneys (Figure 1b). CYP27B1 mRNA expression
increased nearly twofold in uremic kidney (Figure 1a;
Po0.01). Concordant with mRNA, CYP27B1 protein
expression was clearly elevated in uremic kidney
(Figure 1b), indicating that translation of CYP27B1 mRNA
was not impaired in this model.43
Renal CYP24 and CYP27B1 mRNA and protein expression in
uremic rats treated with 1a,25(OH)2D3
We next investigated the regulatory effect of 1a,25(OH)2D3
on these enzymes in uremia. It is well established that
1a,25(OH)2D3 treatment induces CYP24 and attenuates
CYP27B1 expression in vitamin D target tissues, including
kidney.9,28,44 In the uremic kidney, CYP24 mRNA levels were
approximately threefold greater than levels of CYP27B1
(Figure 1c). Administration of 1a,25(OH)2D3 markedly
increased the expression of CYP24 by approximately
12-fold relative to CYP27B1 expression, which increased
only slightly (Figure 1c). Administration of 1a,25(OH)2D3
(0.50 mg/kg) to uremic rats increased mean serum
Table 1 | Biochemical parameters measured in normal vs uremic rats
Nonuremic vehicle Uremic vehicle Uremic +1a,25(OH)2D3
Creatinine (mg/dl) 0.39±0.17 (8) 1.86±0.20 (10)*** 1.38±0.06 (5)**
iPTH (pg/ml) 199±91.3 (10) 521±158.4 (10) 29.6±17.3 (7)w
FGF23 (ng/ml) 0.41±0.02 (10) 21.80±10.3 (8) 138±39.2 (7)***ww
Calcium (mg/dl) 11.04±0.24 (10) 9.72±0.10 (10)** 13.96±0.41 (7)***www
Phosphorus (mg/dl) 10.41±0.16 (10) 14.24±0.98 (10)* 19.04±2.01 (7)***w
Abbreviations: FGF23, fibroblast growth factor 23; iPTH, intact parathyroid hormone; 1a,25(OH)2D3, 1a,25-dihydroxyvitamin D3.
Significant from nonuremic vehicle *(Po0.05) **(Po0.01) ***(Po0.001); significant from uremic vehicle w(Po0.05) ww(Po0.01) www(Po0.001).
Data are presented as mean±s.e.m.; (n) denotes sample size.
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1a,25(OH)2D3 (15.20±3.16 pg/ml uremic to 78.0±12.09pg/ml
uremicþ 1a,25(OH)2D3; Po0.001; Figure 1d), reduced serum
25(OH)D3 (25.90±1.90 ng/ml uremic to 18.10±2.53ng/ml
uremicþ 1a,25(OH)2D3; Po0.05; Figure 1e), improved crea-
tinine and iPTH, and elevated calcium, FGF23 and
phosphorus (Table 1).
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Figure 1 |Uremia induces a strong elevation in basal CYP24 mRNA levels in adenine-treated rats with vitamin D deficiency. (a–e)
Rats were fed a standard or adenine diet (0.75% adenine) for 4 weeks and intravenously administered a daily dose of vehicle (nonuremic
and uremic) or 0.50 mg/kg 1a,25-dihydroxyvitamin D3 (1a,25(OH)2D3) (uremic only) for 7 days beginning at week 4. Serum vitamin D
metabolites and kidneys were collected 24 h after the last dosing. (a) Summary plot of CYP24 and CYP27B1 mRNA expression levels
for nonuremic vehicle (NUþVeh; n¼ 10) and uremic vehicle (UþVeh; n¼ 9) rats. Relative mRNA values are normalized to NUþVeh
(relative expression¼ 1). (b) Kidney lysates prepared from representative nonuremic and uremic vehicle rats were subsequently analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blot with antibodies against CYP24 and CYP27B1. Each lane is
representative of an individual rat kidney fraction. Human kidney lysate was run as a control for CYP27B1. Molecular weights of recognized
bands are indicated. (c) CYP24 and CYP27B1 mRNA levels are presented for UþVeh and uremicþ 1a,25(OH)2D3 (Uþ 1,25D3: n¼ 7 CYP24;
n¼ 6 CYP27B1) groups. Relative mRNA values are normalized to NUþVeh (relative expression¼ 1) in (a). (d) Serum 1a,25(OH)2D3 and
(e) 25-hydroxyvitamin D3 (25(OH)D3) levels in nonuremic and uremic rats treated with vehicle or 1a,25(OH)2D3 are shown. UþVeh (n¼ 10)
was compared with NUþVeh (n¼ 10), whereas Uþ 1,25D3 (n¼ 7 1a,25(OH)2D3; n¼ 6 25(OH)D3) was compared against UþVeh. (f) Rats
were fed a standard or adenine diet (0.75% adenine) for 4 weeks, followed by 8 weeks with a standard diet. Blood was sampled at 2, 4, 6,
and 8 weeks after adenine diet. Average percentage change in 25(OH)D3 levels for NUþVeh (n¼ 8–10) and UþVeh (n¼ 7–10) at 2, 4, 6, and
8 weeks after treatment is shown. Values are normalized to 100% at 2 weeks for each group. (*) Po0.05 (**) Po0.01 (þ þ þ ) Po0.001
represents significant difference. Vitamin D metabolite and CYP24 mRNA values are reported as mean±s.e.m.
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Effect of vitamin D status on renal CYP24 and CYP27B1 gene
and protein expression in uremic vs normal rats
To examine the effect of vitamin D status and uremia on
CYP24 and CYP27B1 expression, rats were fed either a
normal or vitamin D-deficient diet and treated with adenine
or vehicle through oral gavage. Adenine-gavaged animals
exhibited serum chemistries comparable to those observed
in adenine-diet treated animals (data not shown).41 Serum
1a,25(OH)2D3 and 25(OH)D3 levels fell below the limit
of detection in rats fed a vitamin D-deficient diet inde-
pendent of renal status (Table 2). As expected, uremic
rats fed a normal diet exhibited elevated levels of renal
CYP24 mRNA (Figure 2a; Po0.05). Renal CYP24 mRNA
levels in nonuremic vitamin D-deficient rats dropped to
approximately 25% of those observed in nonuremic rats fed a
normal diet, whereas CYP27B1 mRNA levels more than
doubled (Figure 2a and b). Unexpectedly, CYP24 mRNA
remained significantly elevated in vitamin D-deficient uremic
rats (Figure 2b; Po0.01). Moreover, CYP24 protein expres-
sion was augmented in vitamin D-deficient renal tissue from
uremic animals (Figure 2c). Changes in vitamin D status did
not induce any appreciable changes in CYP27B1 mRNA levels
in uremic rats (Figure 2b).
Histological examination of kidney tissue showed
no pathological abnormalities in periodic acid-Schiff-
(Figure 3a), hematoxylin and eosin- (Figure 3b), and
trichrome-stained sections analyzed using light microscopy
in nonuremic rats, irrespective of vitamin D status (Figure 3A
and B). However, uremic (Figure 3aC and bC) and uremic
vitamin D-deficient (Figure 3aD and bD) rats showed
marked intraluminal tubular deposition of brown adenine
crystals. This deposition was accompanied by marked
interstitial inflammation, interstitial fibrosis, and acute
tubular injury on periodic acid-Schiff stain (Figure 3aC and
aD). Glomeruli seemed diffusely ischemic, with shrunken
glomerular tufts and thickened corrugated glomerular
capillary walls. Hematoxylin and eosin staining showed that
the interstitial inflammatory infiltrate consists of mixed
infiltrating leukocytes, including mononuclear cells and
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Figure 2 |Upregulation of basal CYP24 mRNA expression is independent of vitamin D status in uremic rats. (a–c) Rats were fed a
normal or vitamin D-deficient diet for 6 weeks, with both groups dosed orally with adenine (uremic) or vehicle (nonuremic) from week 4 to
6. Vitamin D status was measured at 1 week and kidneys were harvested 2 weeks after adenine treatment. (a) Summary plot of CYP24 and
CYP27B1 mRNA expression in nonuremic (NUþVeh: n¼ 7 CYP24; n¼ 10 CYP27B1) and uremic (UþVeh; n¼ 4) rats fed a normal diet or
(b) vitamin D-deficient diet (NUþVeh: n¼ 7 CYP24; n¼ 10 CYP27B1 and UþVeh: n¼ 9). Relative mRNA values for (a) and (b) are normalized
to NUþVeh rats fed a normal diet (relative expression¼ 1). (c) Kidney lysates prepared from representative NUþVeh and UþVeh vitamin
D-deficient (Vit D-deficient) rats were subsequently analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western
blot with antibodies against CYP24. Each lane is representative of an individual rat kidney fraction. Molecular weight of the recognized band
is indicated. (*) Po0.05 (**) Po0.01 denotes statistical difference. Values are presented as mean±s.e.m.
Table 2 | Serum levels of vitamin D metabolites in nonuremic
or uremic rats fed a normal or vitamin D-deficient diet
Nonuremic vehicle Uremic vehicle
Normal VDD Normal VDD
1a,25(OH)2D3 (pg/ml) 250±49.5 (8) BLD (7) 140±65.0 (4) BLD (9)
25(OH)D3 (ng/ml) 14.4±2.92 (10) BLD (10) 19.2±2.99 (4) BLD (9)
Abbreviations: BLD, below the limit of detection; VDD, vitamin D-deficient diet;
1a,25(OH)2D3, 1a,25-dihydroxyvitamin D3; 25(OH)D3, 25-hydroxyvitamin D3.
Data are presented as mean±s.e.m.; (n) denotes sample size.
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occasional neutrophils (Figure 3bC and bD). On trichrome
staining, there was marked interstitial fibrosis in uremic and
uremic vitamin D-deficient rats (data not shown). This was
seen in parallel to severe tubular dilatation, microcystic
change, and foci of tubular atrophy.
Normal control and nonuremic vitamin D-deficient rats
showed proximal tubular staining of CYP24 (2þ ) that was
predominantly located along the cell membrane at the apical
(luminal) aspect of epithelial cells (Figure 4a and b). There
was no significant glomerular or vascular staining for CYP24.
In contrast, kidneys from uremic and uremic vitamin
D-deficient rats showed not only apical staining of proximal
tubular epithelial cells (2þ ) but also cytoplasmic staining of
the same cells (2þ to 3þ ) (Figure 4c and d). In addition,
thick ascending distal tubular epithelial cells showed immuno-
peroxidase staining (2þ ) in these groups of animals.
Renal CYP24 protein expression in CKD patients and normal
age-matched controls
Kidney biopsy samples from patients with CKD and normal
age-matched controls were examined for CYP24 renal
expression by immunohistochemistry. CYP24 staining was
highly localized to the apical membrane (1þ to 2þ ) in
proximal tubules in control tissue (Figure 5aA), whereas
CKD tissue showed marked (2þ to 3þ ) and diffuse
cytoplasmic staining in the proximal tubular (Figure 5aB),
as well as cortical (Figure 5bB) and medullary (Figure 5cB)
distal tubules in six of eight biopsy samples. In most biopsy
samples, mural staining in the interlobular arteries was
evident and seemed to be intracytoplasmic in arterial wall
smooth muscle cells. Interstitial staining in three of eight
biopsy samples was focally present (data not shown). The
intensity of immunostaining of CYP24 was not associated
with the clinical parameters outlined in Table 3.
DISCUSSION
Vitamin D insufficiency is highly prevalent in CKD patients
and may contribute significantly to the morbidity14–16 and
mortality associated with this disease.17–20 Although reduced
exposure to sunlight and vitamin D intake are important
factors contributing to insufficiency, disruptions in the
Figure 3 |Histopathological examination of normal and
uremic kidney from rats fed a normal or vitamin D-deficient
diet. (a) Periodic acid-Schiff and (b) hematoxylin and eosin staining
of kidneys of nonuremic (A, B) or adenine-treated (C, D) rats fed a
normal (A, C) or vitamin D-deficient (B, D) diet. Nonuremic control
groups received normal or vitamin D-deficient diet for 6 weeks
before harvesting the kidneys. Uremic animals received a normal
or vitamin D-deficient diet for 8 weeks, with a daily gavage of
100mg adenine occurring during weeks 5 and 6. In all groups
n¼ 4. Harvested kidneys were fixed in formalin and stored in 70%
ethanol before histolopathological examination. Original
magnification  10. Arrows (C, D) designate intraluminal 2,8
dihydroxyadenine crystals.
Figure 4 | Immunostaining of CYP24 protein in uremic kidney
is widely distributed independent of vitamin D status.
Immunoperoxidase staining for CYP24 in normal (a, b) or adenine-
treated (c, d) rats fed normal (a, c) or vitamin D-deficient (b, d)
diet. Nonuremic control groups received a normal or vitamin
D-deficient diet for 6 weeks before harvesting the kidneys. Uremic
animals received a normal or vitamin D-deficient diet for 8 weeks,
with a daily gavage of 100mg adenine occurring during weeks
5 and 6. All groups n¼ 4. Harvested kidneys were fixed in formalin
and stored in 70% ethanol before immunohistochemical analysis.
Original magnification  40.
Kidney International (2010) 78, 463–472 467
CF Helvig et al.: CYP24 expression is elevated in uremic kidney o r ig ina l a r t i c l e
synthesis and catabolism of 25(OH)D3 and 1a,25(OH)2D3
may also have considerable etiological roles. Altered expres-
sion or activity of CYP27B1 has previously been implicated in
reduced blood levels of 1a,25(OH)2D3 in patients
21,22 and
animal models of CKD;45 however, recent evidence suggests
that aberrant CYP27B1 expression cannot entirely account
for low 1a,25(OH)2D3 levels or explain 25(OH)D3 depletion
in kidney disease.23,46 Our studies show that elevated renal
expression of CYP24 induced by factors associated with the
uremic state may have an important effect on vitamin D
status and may possibly affect tissue responsiveness to
vitamin D therapy.
The adenine rat model is a recently established animal
model of CKD that closely mimics several clinical features
of secondary hyperparathyroidism,40–42 a serious complica-
tion arising from declining renal function in CKD patients.
Adenine-treated rats in our study showed pathology
consistent with secondary hyperparathyroidism, including
elevated iPTH and FGF23 levels, hypocalcemia and hyper-
phosphatemia, as well as a comparative decline in both serum
levels of 1a,25(OH)2D3 and 25(OH)D3 over time.
Depletion of 1a,25(OH)2D3 in CKD patients has long been
ascribed to reduced CYP27B1 activity caused by decreased
renal mass,47–49 inadequate 25(OH)D3 availability,
48 suppres-
sion,50,51 and/or dysregulation of CYP27B1 expression.52
Interestingly, in our study, both renal CYP27B1 mRNA and
protein levels were elevated in adenine-fed rats, suggesting
that observed decreases in blood levels of 1a,25(OH)2D3 were
not due to changes in CYP27B1 expression. Previous studies
using a kidney remnant model of early-stage CKD showed
that CYP27B1 levels rose in conjunction with plasma iPTH
levels.46 In this model, however, 1a,25(OH)2D3 levels
remained unchanged, indicating that the increase in CYP27B1
could effectively compensate for the loss of total CYP27B1
associated with the reduction in kidney mass. The observed
increase in CYP27B1 expression in adenine-treated animals
may similarly reflect a compensatory response to reduced
blood levels of 1a,25(OH)2D3, although an unsuccessful one.
Zehnder et al.23 recently reported increased CYP27B1 mRNA
expression in renal biopsy tissue from patients with kidney
disease and significantly depleted circulating 1a,25(OH)2D3
levels, possibly also reflecting unsuccessful compensatory
responses to low vitamin D status. Given the usual strong
correlation between expression of renal CYP27B1 mRNA and
synthesis of 1a,25(OH)2D3,
53,54 these findings suggest that
CYP27B1 may be adequately expressed in the uremic state,
but its effectiveness to generate ample 1a,25(OH)2D3 is
compromised.
Elevated CYP24 expression levels in the uremic kidney in
combination with low vitamin D status may reflect
accelerated catabolism of 1a,25(OH)2D3 and 25(OH)D3
by CYP24. Although CYP24 activity was not directly
evaluated in our study, previous studies have shown an
inverse relationship between renal CYP24 mRNA and
1a,25(OH)2D3 concentration, as well as increased renal side
chain oxidation of 1a,25(OH)2D3 in tissues expressing
abnormally high levels of CYP24.53,55–57 The importance of
CYP24 in regulating vitamin D status has been further
demonstrated in the CYP24 knockout mouse, in which null
Control CKD
Figure 5 | Immunohistochemistry demonstrating elevated
CYP24 protein expression in renal biopsy tissue from patients
with chronic kidney disease (CKD). Immunperoxidase staining
of CYP24 protein in the (a) renal artery, (b) cortical tubules, and
(c) medulla from patients with renal disease (n¼ 8) and age-
matched controls (n¼ 8) is presented. Arrows indicate localized
CYP24 staining to the apical membrane of the proximal tubules in
control tissue (arrows; a, A). Diseased tissue showed marked and
diffuse cytoplasmic staining in the proximal tubular (arrows; a, B),
as well as cortical (b, B) and medullary (c, B) distal tubules. Original
magnification was  400 for artery and  200 for medulla and
cortical tubules.
Table 3 | Biochemical parameters measured in patients with
CKD
Clinical characteristics Control CKD
Phosphorus (mg/dl) 3.37±0.34 (8) 3.78±0.28 (8)
Calcium (mg/dl) 9.64±0.32 (8) 9.30±0.48 (8)
Creatinine (mg/dl) 1.20±0.2 (8) 2.40±0.40 (8)*
Abbreviations: CKD, chronic kidney disease. Measured in serum; significant from
control *(Po0.05).
Data are presented as mean±s.e.m.; (n) denotes sample size.
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animals exhibit high ambient levels of 1a,25(OH)2D3.
26,27
Given the strong inverse relationship between CYP24
expression levels and vitamin D status, reduced blood levels
of 1a,25(OH)2D3 in certain diseases may represent vitamin D
insufficiency as a consequence of aberrant expression levels of
CYP24. For example, although suppression of CYP27B1
caused by abnormally high levels of circulating FGF23 has
been proposed to be a potential factor delineating vitamin D
status in genetic hypophosphatemia,50,58 additional elevation
in the renal expression of CYP24 may also contribute to
reduced 1a,25(OH)2D3 and 25(OH)D3. In the Hyp
mouse, which is a rodent model of human X-linked
hypophosphatemic rickets, high kidney levels of CYP24
mRNA and immunoreactive protein have been observed
and are proposed to be major mechanisms underlying
accelerated degradation of 1a,25(OH)2D3.
32,33,57 Growing
evidence indicates that basal CYP24 expression can also be
abnormally high in various forms of cancer and may
be a primary determinant of vitamin D deficiency and
decreased responsiveness of tumor cells to 1a,25(OH)2D3
treatment.34–39
Our findings, in particular, the strong expression of
CYP24 in kidney tissue from uremic patients, suggest that
CYP24 may have a greater role in causing vitamin D
insufficiency in CKD patients than has been previously
suspected. Interestingly, immunohistochemical analyses
indicate that CYP24 protein seems more widely expressed
in the uremic kidney, showing apical staining of both
proximal and distal tubule epithelial cells with a stronger
apparent cytoplasmic component. Cytoplasmic expression of
elevated CYP24 protein has also been reported in human
colorectal cancer tissue after malignant transformation, as
well as in breast cancer tissue.37,38 The widespread expression
of CYP24 in uremic kidney may have a direct impact on
kidney exposure to vitamin D hormone. If elevated CYP24
functions to devoid the kidney tissue of both 25(OH)D3, and
1a,25(OH)2D3, progression of kidney disease may be
accelerated through the promotion of pathological processes,
such as fibrosis and inflammation, which can normally be
suppressed, at least to some extent, by vitamin D hormones.
It is unexpected that adenine-treated animals exhibited
similar renal CYP24 mRNA and protein expression irrespec-
tive of vitamin D status. This is in marked contrast to the
very low levels of CYP24 expression seen in otherwise normal
rats fed a vitamin D-deficient diet. These findings indicate
that mechanisms other than 1a,25(OH)2D3 are also involved
in the regulation of CYP24 in the uremic kidney. One
possible candidate is the phosphaturic hormone FGF23,
which can indirectly modulate 1a,25(OH)2D3 levels by
controlling the expression of CYP27B1 and CYP24.50,58,59
Previous studies have shown that disease models character-
ized by elevated circulatory FGF23 levels, such as X-linked
hypophosphatemic rickets31,32 and autosomal-dominant
hypophosphatemic rickets,60 as well as animals overexpres-
sing FGF2361 or injected with a bolus dose of FGF23,50
exhibit increased basal levels of renal CYP24 coincident with
reduced serum levels of 1a,25(OH)2D3. FGF23 levels are also
significantly elevated in serum of adenine-treated animals,
and can be, in part, responsible for elevated basal CYP24
expression in this model.
The present study shows that kidney tissue from either
rats exposed to adenine or biopsy samples from human CKD
patients exhibit significant upregulation in basal CYP24
mRNA and protein expression, which may have an impact on
vitamin D status, as well as deprive kidneys of local exposure
to vitamin D hormone. These findings suggest that the
vitamin D-degrading catabolic enzyme CYP24 may be an
important determinant of vitamin D status, kidney tissue
resistance to hormone therapy and progression of kidney
disease. Furthermore, they suggest that use of CYP24
inhibitors alone or in combination with 1a,25(OH)2D3 or
other vitamin D analogs may provide a means of overcoming
such resistance and maintaining optimal levels of vitamin D
metabolites in CKD patients.
MATERIALS AND METHODS
Animals and diet
Adult male Sprague–Dawley rats (6–8 weeks of age) were purchased
from Hilltop Lab Animals Inc. (Scottdale, PA, USA). All animals
had access to food and water ad libitum. The standard diet
contained 0.80% calcium and 0.60% phosphorus (PMI Certified
Rodent Diet 5002; PMI Nutrition International Inc., St Louis, MO,
USA). Rats were fed a standard diet containing 0.75% adenine to
induce uremia, a purified diet devoid of vitamin D3 to induce
vitamin D deficiency (TestDiet, Richmond, IN, USA; AIN-93M/No
Vitamin D), or the same vitamin D-deficient diet supplemented
with 1 IU/g vitamin D3 (TestDiet; AIN-93M Maintenance).
Diets with altered vitamin D content contained 0.50% calcium
and 0.30% phosphorus.
Experimental procedures in vivo
In one study, rats were fed a standard diet alone or containing 0.75%
adenine for a total of 4 weeks to determine enzyme expression in
uremic and normal tissue. After 3 weeks on these diets, uremic and
nonuremic rats were treated intravenously daily with 0.50mg/kg
1a,25(OH)2D3 (Sigma–Aldrich/Fluka, St Louis, MO, USA) or
vehicle (propylene glycol/saline/ethanol (30:50:20 v/v/v)) for 7 days.
Serum or plasma was sampled from the tail-vein and organs were
collected in RNAlater (Ambion Inc., Austin, TX, USA) at 24 h after
final injection.
In a second study, rats were fed a standard diet alone or
containing 0.75% adenine for a total of 4 weeks, then returned to
standard diet for up to 8 weeks. Serum was sampled from the tail
vein at 2, 4, 6, and 8 weeks after adenine diet to investigate changes
in 25(OH)D3 levels over time.
To explore the effects of vitamin D deficiency on enzyme
expression in uremic and nonuremic kidney, rats were fed a purified
diet devoid of vitamin D3 for 6 weeks or maintained on a matching
diet supplemented with vitamin D3. After 4 weeks, some vitamin
D-deficient and -sufficient rats were administered an adenine
suspension (100mg/ml adenine hemisulfate in H2O; Sigma–Aldrich,
St Louis, MO, USA) orally once per day to induce uremia or given
vehicle (100% H2O) by oral gavage for 2 weeks. Vitamin D status
was measured at 1 week and kidneys were harvested at 2 weeks after
adenine treatment.
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Real-time polymerase chain reaction (PCR)
Aliquots of RNAs were reverse transcribed using random hexamers
and Thermoscript Reverse Transcriptase according to the manu-
facturer’s instructions (Invitrogen, Carlsbad, CA, USA). Quantita-
tive real-time PCR was performed using an ABI Prism 7000
sequence detection system (Applied Biosystems (ABI), Foster City,
CA, USA) using Taqman Universal PCR Master Mix (ABI #4304437)
according to the manufacturer’s instructions. Taqman gene expres-
sion assays (ABI) with the following ID numbers were used: human
glyceraldehyde 3-phosphate dehydrogenase, Hs99999905_m1;
human CYP24, Hs00167999_m1; rat CYP24 Rn01423141_g1; rat
CYP27B1 Rn00587137_m1; mouse glyceraldehyde 3-phosphate
dehydrogenase, Mm99999915_g1; mouse CYP24, Mm00487244_m1;
mouse CYP27B1, Mm01165919_g1. PCR reaction volumes of 20 ml
were used with 50 cycles of amplification. Each cDNA sample was
tested in duplicate or triplicate. Quantitative real-time-PCR results
were analyzed using sequence detection system software V1.0 (ABI).
Gene expression levels were calculated using the comparative cycle
threshold method, and normalized to glyceraldehyde 3-phosphate
dehydrogenase expression levels.
Preparation of rat kidney lysate and western blot analysis
Rat kidneys stored at 201C in RNAlater were rinsed with
phosphate-buffered saline and subsequently homogenized in a
prechilled buffer composed of 25mM 4-(2-hydroxylethyl)-1-piper-
azineethanesulfonic acid (pH 7.8), 150mM KCl, 2mM ethylenedia-
minetetraacetic acid, 10% glycerol, 1.0% Triton X-100, and 0.1%
sodium dodecyl sulfate. Protease inhibitor cocktail set III (EMD
Biosciences, San Diego, CA, USA) was diluted to a ratio of 1:100 and
added to the buffer immediately before homogenization. The
resultant homogenates were centrifuged for 30min at 18,000 g to
remove insoluble materials. The protein concentration of the
clarified lysates was determined using a detergent-compatible Lowry
assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Equal
amounts of kidney lysates (15 mg) from representative animals were
subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and transferred to nitrocellulose membranes. After
incubation with the monoclonal antibody to CYP24 (Abnova Corp.,
Taipei, Taiwan) or with the rabbit polyclonal antibody to CYP27B1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), appropriate
horseradish peroxidase-conjugated secondary antibodies were
applied and recognized proteins were subsequently detected by
chemiluminescence (GE Healthcare, Piscataway, NJ, USA).
Human kidney lystate (Biochain, Hayward, CA, USA) was used as
a control for CYP27B1 experiments. Molecular weights were
estimated using Precision Plus Protein WesternC standards (Bio-
Rad Laboratories).
Histopathology and immunohistochemisty of rat tissue
Rat kidneys were bisected and immediately placed in 4% neutral-
buffered formalin for 24h, followed by 70% ethanol. All formalin-fixed
paraffin-embedded kidneys were stained with periodic acid-Schiff
reaction, hematoxylin and eosin, and Masson’s trichrome stains and
examined by light microscopy. Formalin-fixed, paraffin-embedded
sections from rat kidneys were used for all immunohistochemical
analysis. Heat-induced antigen retrieval was used. Endogenous
peroxidase activity was prevented by pretreating all sections
with 3% hydrogen peroxide. Anti-CYP24 primary antibody (M02)
(Abnova) was used at a dilution of 1:2000. Negative controls,
with no primary antibody added, were used for all immunohisto-
chemical staining. Immunoperoxidase staining for CYP24 was
scored using a compartmental schema with staining intensity
graded from 0 (no staining), 1þ (mild), 2þ (moderate), to 3þ
(marked).
Human renal tissue from normal individuals and from
patients with renal disease
Institutional ethics board approval was granted for the use of
archived biopsy tissue from the University Health Network
(Toronto, Ontario, Canada). Renal tissue was obtained from patients
with diabetic nephropathy (Table 3) and from normal age-matched
controls. Patients were not taking active 1a,25(OH)2D3, additional
vitamin D analoges and/or bisphosphonates, whereas five of eight
diabetic patients and one of eight age-matched controls were
currently taking angiotensin-converting enzyme inhibitors and/or
angiotensin II receptor blockers. Formalin-fixed paraffin-embedded
sections of renal biopsy samples were cut at 3 mm, followed by heat-
induced antigen retrieval. Sections were incubated with monoclonal
anti-CYP24 (Abnova Corp.). To eliminate any potential nonspecific
biotin activity, slides were stained with a secondary antimouse
antibody (Dako, Glostrup, Denmark) using the EnVision system
(Dako). Endogenous peroxidase activity was prevented by pretreat-
ing with 3% hydrogen peroxide. Negative controls with irrelevant
primary antibody and no primary antibody were used. Immuno-
peroxidase staining intensity was graded as shown above.
Blood biochemistry
Serum samples of 25(OH)D3 and 1a,25(OH)2D3 were spiked with
[26,27-2H6] 25(OH)D3 or [25,26-
2H6] 1a,25(OH)2D3 and dissolved
in acetonitrile to serve as an internal standard. 1a,25(OH)2D3 or
25(OH)D3 and internal standards were extracted from serum using
Accubond II ODS-C18 100mg, 1ml SPE cartridges (Agilent
Technologies, Palo Alto, CA, USA). The collected fractions were
dried under a steady stream of nitrogen gas, residues reconstituted
in 50 ml of methanol/H2O (80/20; v/v) and analyzed using LC-MS/
MS (Waters Alliance HPLC-Waters Quattro Ultima Mass Spectro-
meter, Milford, MA, USA). Creatinine levels were measured using a
sarcosine oxidase-based enzymatic assay (Roche Diagnostics, Laval,
QC, Canada). Plasma iPTH levels were determined using the rat
iPTH ELISA kit (Immutopics, San Clemente, CA, USA). Serum FGF23
was measured using an FGF23 ELISA kit (Kainos Laboratories, Tokyo,
Japan) as per the manufacturer’s instructions. Serum phosphorus
and calcium levels were determined using an o-cresolphthalein
complexone-based assay and an ammonium molybdate-based assay
(Pointe Scientific, Canton, MI, USA), respectively.
Statistical analysis
To calculate fold induction, nonuremic vehicle values were normal-
ized to 1 unless otherwise specified. Student’s independent t-test was
used to assess the difference between two groups, whereas multiple
groups were assessed using one-way ANOVA, with Bonferroni’s
multiple group comparison after test. The level of significance was
set at Po0.05 (Graphpad Prism 5, La Jolla, CA, USA). n denotes
sample size and data are presented as mean±s.e.m.
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